Comparision of airway administration of drug to open up premature lungs (surfactant) with and without steroids in preventing chronic lung disease in premature babies
- Conditions
- Health Condition 1: J984- Other disorders of lung
- Registration Number
- CTRI/2020/02/023310
- Lead Sponsor
- OT APPLICABLE
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1.Less than 6 hours of age
2.Receiving mechanical ventilation via an endotracheal tube or non-invasive respiratory support including CPAP, NIPPV and a clinical decision to treat the infant with exogenous surfactant (first or subsequent dose) for RDS
3.Prospective, written, informed parental/guardian consent obtained
1.Extreme preterm <24 weeks of gestation
2.Infant is considered non-viable or is not going to be admitted to intensive care
3.Known or suspected major congenital anomaly that is likely to affect respiratory status (eg: upper airway obstruction, severe pulmonary hypoplasia following oligohydramnios, congenital lung malformation, major congenital heart disease).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method